Updates

Axon regularly advises spin-outs from academic institutions on a wide range of topics. We make sure that the spin-out’s license agreement includes commercially and legally viable terms and is attractive to investors. In addition, we advise on the corporate structure of the spin-out, balancing the interest of the founders, the academic institution and all other stakeholders.

Axon assisted a Dutch IVD company in securing a EUR 24M equity financing round, advising on the transaction structure, investment documentation and related matters.

Axon assisted a Dutch cultivated materials company in securing a EUR 22M Series A financing round. We advised on the transaction structure, investment documentation and related matters.

Axon assisted a Dutch oncology company, developing small molecule inhibitors for the precision treatment of cancer, with the structuring and completion of its Series A financing round. We advised on the drafting of all corporate resolutions, conditions precedent and related filtering and closing matters.

Axon acted on behalf of an investor in connection with their investment in a clinical-stage biotech company developing first-in-class therapeutics and diagnostics for fibrosis. We conducted legal due diligence on the target company and reviewed the transaction documentation on behalf of the investors.

Axon assisted the shareholders of a Dutch medtech company, specialising in epilepsy detection devices, in the sale of the company to a Scandinavian healthcare technology group. We advised on the transaction structure, share purchase documentation and related matters.